Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: xray who wrote (554)	5/7/1998 3:14:00 PM
From: Paul S.	Read Replies (2) \| Respond to of 1185

The news is out. US$ 86.5 million licensing deal with Hoffman Leroche. Good job Nortran.

To: xray who wrote (554)	5/7/1998 3:19:00 PM
From: David Culver	Respond to of 1185

Thanks Allen For a small group of scientists it would appear that NRT has done some very good science. A friend was in the UK a few months ago and s scientist commented on some of the very good small biotech companies around Vancouver. NRT is obviously one of them. I assume it is also a complement to UBC. Dave

To: xray who wrote (554)	5/8/1998 11:04:00 PM
From: xray	Respond to of 1185

Just a note: If you are not able to assess the validity of the science by speaking with company scientists or visiting the company, you may wish to read some of the papers published, such as: Better antiarrhythmics? Development of antiarrhythmic drugs selective for ischaemia-dependent arrhythmias Drug Dev. Res. 42:198-210, 1997. Available from libraries or by registering at www2.interscience.wiley.com (P.S. Jay has visited Nortran labs and discussed the science and commercialisation plans in some detail, albeit some time ago.)